Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai said on Friday that they have launched a new large-scale human genome sequencing research project with New York-based biotechnology company Regeneron.

According to the news on August 8, Beijing Savant Biotechnology Co., ltd. (Stock Code No.: 873748) was listed on the New OTC Market.

Lucira Health announced on Thursday that it has received authorization under an interim order from Health Canada to market the Lucira COVID-19 & Flu Test for emergency use.

Roche announced on Thursday that it has received approval from the US Food and Drug Administration for a label expansion of its Ventana MMR RxDx Panel to determine which solid tumor patients could benefit from treatment with Merck's Keytruda (pembrolizumab).

Recently, Suzhou Hybiome Biomedical Engineering Co., Ltd. announced the completion of the Pre-IPO round of financing with CNY 100 million. Huatai United Securities acted as the financial advisor in this transaction and introduced investor Zhongrong Trust Dingxin to Hybiome.

Becton Dickinson announced on Tuesday that it has signed a collaboration agreement with Laboratory Corporation of America to develop flow cytometry-based companion diagnostics.

Molecular testing company Predicine said on Tuesday that its blood and urine cell-free DNA (cfDNA) assay, PredicineCare, has secured a CE-IVD mark.

Recently, the localization project of QIAGEN has received another good news. The automatic nucleic acid extraction instrument QIAcube HT has been received the first-class medical device filing approval

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics

Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life